Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective for obese patients with type 2 diabetes mellitus (T2DM) because they concomitantly target obesity and dysglycaemia. Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T2DM, we determined the impact of 6 months' GLP-1 RA therapy on intrahepatic lipid (IHL) in obese, T2DM patients with hepatic steatosis, and evaluated the inter-relationship between changes in IHL with those in glycosylated haemoglobin (HbA(1)c), body weight, and volume of abdominal visceral and subcutaneous adipose tissue (VAT and SAT). We prospectively studied 25 (12 male) patients, age 50±10 years, BMI 38.4±5.6 kg/m(2) (mean ± SD) with baseline IHL of 28.2% (16.5 to 43.1%) and HbA(1)c of 9.6% (7.9 to 10.7%) (median and interquartile range). Patients treated with metformin and sulphonylureas/DPP-IV inhibitors were given 6 months GLP-1 RA (exenatide, n = 19; liraglutide, n = 6). IHL was quantified by liver proton magnetic resonance spectroscopy ((1)H MRS) and VAT and SAT by whole body magnetic resonance imaging (MRI). Treatment was associated with mean weight loss of 5.0 kg (95% CI 3.5,6.5 kg), mean HbA(1c) reduction of 1·6% (17 mmol/mol) (0·8,2·4%) and a 42% relative reduction in IHL (-59.3, -16.5%). The relative reduction in IHL correlated with that in HbA(1)c (ρ = 0.49; p = 0.01) but was not significantly correlated with that in total body weight, VAT or SAT. The greatest IHL reduction occurred in individuals with highest pre-treatment levels. Mechanistic studies are needed to determine potential direct effects of GLP-1 RA on human liver lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the observed reduction in liver fat content (6.2%) in the GLP-1RA arm is similar to previous studies in people with MASLD,23,24”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with exenatide reduced liver steatosis [109,146,150] and when added to pioglitazone, an oral hypoglycemic and insulin sensitizing drug approved for the treatment of T2D that acts on nuclear peroxisome proliferator activated receptor-gamma (PPAR-γ) [147], potentiated the known action of pioglitazone in reducing hepatic fat [92].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [150]
In the citing paper
“Liraglutide promoted weight loss and beneficially altered the fat distribution by decreasing waist circumference, waist/hip ratio, and the amount of subcutaneous and visceral fat content and liver steatosis [145,150,152,155].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“GLP-1 acts through several distinct mechanisms including stimulation of glucose-dependent insulin secretion, inhibition of glucagon secretion, delay of gastric emptying and promotion of weight loss through central inhibition of appetite [1].”
BackgroundDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“A further possibility, consistent with the correlation we observed between effects on IHL and HBA1c, is that the effects on IHL are secondary to improved glucose tolerance, with reduced hyperinsulinemia (and perhaps reduced hyperglycaemia), reducing the increased rate of hepatocyte lipogenesis characteristic of these…”
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089 · cited 1×
“NAFLD describes a disease spectrum with excessive deposition of fat within the liver (hepatic steatosis), which may be associated with inflammation, cell death, and fibrosis (non-alcoholic steatohepatitis, NASH), ultimately progressing to cirrhosis [3].”
BackgroundA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562 · cited 13×
“Reproducibility of MRI and MRS Analysis Volumetric analysis of adipose tissue content: the mean coefficient of variations (CoV) were determined as total body fat, 1–2%; total subcutaneous fat, 3–4%; abdominal subcutaneous fat, 1–3%; visceral fat, 6–8%.”
MethodInfluentialBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164 · cited 1×
“dietary intervention consisting of a 600 kcal diet, liver fat reduced by a total of 7065% [35].”
BackgroundPetersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Bugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., & Marchesini, G. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41583.x · Cited by 691 · cited 1×
“Treatment with metformin or glitazone (either rosiglitazone or pioglitazone) may also ameliorate NAFLD, with metabolic and histological improvement, predominantly through reduced steatosis and inflammation, with little effect on fibrosis [22–25].”
BackgroundMeasurement of intracellular triglyceride stores by H spectroscopy: validation in vivo
Szczepaniak, L. S., Babcock, E. E., Schick, F., Dobbins, R. L., Garg, A., Burns, D. K., McGarry, J. D., & Stein, D. T. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.5.e977 · Cited by 688 · cited 1×
“Fat quantification by H MRS has been validated against gold standard biochemical measurements [32].”
Method
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Takaki, A., Kawai, D., & Yamamoto, K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141020704 · Cited by 447
“patients with NAFLD caused a reduction in intrahepatic lipid content that correlated with diabetic control [96].”
BackgroundNevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262
“[19] found a correlation between HTGC and HbA1c change, but not with weight change in 25 subjects with T2D treated with exenatide or liraglutide for 6 months.”
BackgroundBallestri, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1724 · Cited by 262
The Protective Role of Butyrate against Obesity and Obesity-Related Diseases
Coppola, S., Avagliano, C., Calignano, A., & Berni Canani, R. (2021) · Molecules · doi:10.3390/molecules26030682 · Cited by 261
“Through the activation of GPCR (GLP-1R), GLP-1 exerts its effects in lipid metabolism, protecting hepatocytes against steatosis [148,149]: HFD and lipotoxicity, typical of obesity, induce the loss of GLP-1 responsiveness, but butyrate has the capability to upregulate hepatic GLP-1R expression, with a decrease in fatty…”
BackgroundYan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260
DiNicolantonio, J. J., Bhutani, J., & O'Keefe, J. H. (2015) · Open Heart · doi:10.1136/openhrt-2015-000327 · Cited by 228
Petit, J.-M., Cercueil, J.-P., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 227
“(14), only 6 patients were treated with liraglutide.”
BackgroundLiang, Z., Wu, Q., Chen, B., Yu, P., Zhao, H., & Ouyang, X. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.04.005 · Cited by 206
Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097554 · Cited by 186
“Liraglutide also stimulates the satiety response [7], inhibits gastric emptying [7,8], reduces intrahepatic lipid levels [9], induces weight loss [5], and improves several markers of vascular function [10].”
BackgroundKoutoukidis, D. A., Koshiaris, C., Henry, J. A., Noreik, M., Morris, E., Manoharan, I., Tudor, K., Bodenham, E., Dunnigan, A., Jebb, S. A., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154455 · Cited by 186
Shao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185
“Patients treated with GLP-1 receptor agonists maintained a weight loss predominantly associated with a direct reduction in adipose tissue [28,29].”
BackgroundEguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182
Pathophysiology of Non Alcoholic Fatty Liver Disease
Petta, S., Gastaldelli, A., Rebelos, E., Bugianesi, E., Messa, P., Miele, L., Svegliati-Baroni, G., Valenti, L., & Bonino, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122082 · Cited by 170
“Abbreviations AG acylated ghrelin AMPK adenosine monophosphate-activated protein kinase ANP atrial natriuretic peptide BAT brown adipose tissue BMI body mass index CIMT carotid intima-media thickness CKD chronic kidney disease CRP C-reactive protein DAG diacyl glycerol DeAG des-acylated ghrelin DKD diabetic kidney dis…”
BackgroundSeufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
Chen, X., Chen, C., & Fu, X. (2022) · Food & Function · doi:10.1039/d2fo02300h · Cited by 167
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4100-7 · Cited by 142
“With an expected reduction in the percentage of steatosis of approximately 50% [5], a total of 13 patients per treatment arm were needed (parallel-group design, α= 0.”
Feng, W., Bi, Y., Li, P., Yin, T., Gao, C., Shen, S., Gao, L., Yang, D., & Zhu, D. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12888 · Cited by 139
Bowden Davies, K. A., Sprung, V. S., Norman, J. A., Thompson, A., Mitchell, K. L., Halford, J. C. G., Harrold, J. A., Wilding, J. P. H., Kemp, G. J., & Cuthbertson, D. J. (2018) · Diabetologia · doi:10.1007/s00125-018-4603-5 · Cited by 138
Self-citationCuthbertson, D. J., Shojaee-Moradie, F., Sprung, V. S., Jones, H., Pugh, C. J. A., Richardson, P., Kemp, G. J., Barrett, M., Jackson, N. C., Thomas, E. L., et al. (2016) · Clinical Science · doi:10.1042/cs20150447 · Cited by 138
Self-citationGLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway
He, Q., Sha, S., Sun, L., Zhang, J., & Dong, M. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.05.086 · Cited by 147
Liu, J., Xu, Y., Hu, Y., & Wang, G. (2014) · Metabolism · doi:10.1016/j.metabol.2014.11.009 · Cited by 145
Tang, A., RABASA-LHORET, R. P. R., Castel, H., Wartelle‐Bladou, C., Gilbert, G., Massicotte-Tisluck, K., Chartrand, G., Olivié, D., Julien, A., de Guise, J. A., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2548 · Cited by 144
“Prior studies suggested that GLP1 receptor agonists, such as liraglutide and exenatide, would improve liver steatosis in animal models (27,28), in human case series (29), and in prospective nonrandomized trials (30,31).”
BackgroundMolecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
Takaki, A., Kawai, D., & Yamamoto, K. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15057352 · Cited by 138
“A GLP-1 receptor agonist in type 2 diabetic patients with NAFLD caused a reduction in intrahepatic lipid content that correlated with diabetic control [118].”
BackgroundBizino, M. B., Jazet, I. M., de Heer, P., van Eyk, H. J., Dekkers, I. A., Rensen, P. C. N., Paiman, E. H. M., Lamb, H. J., & Smit, J. W. (2020) · Diabetologia · doi:10.1007/s00125-019-05021-6 · Cited by 123
Guo, W., Tian, W., Lin, L., & Xu, X. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108487 · Cited by 126
Liu, L., Yan, H., Xia, M., Zhao, L., Lv, M., Zhao, N., Rao, S., Yao, X., Wu, W., Pan, B., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3292 · Cited by 127
“5% and insulin glargine decreased LFC by about 3 ± 3%.(14,18) We estimated”
BackgroundSomm, E., Montandon, S. A., Loizides-Mangold, U., Gaïa, N., Lazarevic, V., De Vito, C., Perroud, E., Bochaton-Piallat, M.-L., Dibner, C., Schrenzel, J., et al. (2021) · Translational Research · doi:10.1016/j.trsl.2020.07.008 · Cited by 118
Energy balance and metabolic changes with sodium‐glucose co‐transporter 2 inhibition
Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12578 · Cited by 116
“The metabolic changes also suggest that fat may be metabolized selectively, leading to the hypothesis that liver fat may be preferentially reduced with SGLT2 inhibition [83].”
BackgroundSelf-citationSIRT1 Mediates the Effect of GLP-1 Receptor Agonist Exenatide on Ameliorating Hepatic Steatosis
Xu, F., Li, Z., Zheng, X., Liu, H., Liang, H., Xu, H., Chen, Z., Zeng, K., & Weng, J. (2014) · Diabetes · doi:10.2337/db14-0263 · Cited by 114
“Accumulated evidence demonstrate that it could improve lipid deposition and inflammation in liver effectively (6,7,28), which indicates GLP-1 and its mimetics could be a potential drug for the treatment of NAFLD, especially in NAFLD combined with T2DM (29,30).”
Pharmacological management of nonalcoholic fatty liver disease
Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114
Chen, X., Chen, C., & Fu, X. (2022) · Food & Function · doi:10.1039/d2fo02298b · Cited by 116
Bernsmeier, C., Meyer‐Gerspach, A. C., Blaser, L. S., Jeker, L., Steinert, R. E., Heim, M. H., & Beglinger, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087488 · Cited by 118
“Recently, improvement of lipid accumulation, assessed by liver proton magnetic resonance spectroscopy ((1)H-MRS), has been shown in patients with T2DM treated with GLP-1 agonists [21].”
BackgroundLundkvist, P., Sjöström, C. D., Amini, S., Pereira, M. J., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12779 · Cited by 108
“Exenatide treatment has also been reported to reduce liver fat over 6 months by −18%.(30) The adipose tissue reductions found in this study are generally compatible with previous observations of dapagliflozin and exenatide individually, although the numeric reduction in liver fat with dapagliflozin/exenatide was not s…”
ResultWang, X.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14821 · Cited by 109
Ranjbar, G., Mikhailidis, D. P., & Sahebkar, A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154001 · Cited by 107
Heuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106
Exenatide: pharmacokinetics, clinical use, and future directions
Knop, F. K., Brønden, A., & Vilsbøll, T. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1282463 · Cited by 118
“001) [67], indicating a reduction in liver damage.”
BackgroundZhang, J.-M., Sun, Y.-S., Zhao, L.-Q., Chen, T.-T., Fan, M.-N., Jiao, H., Zhao, J.-P., Wang, X.-J., Li, F.-C., Li, H.-F., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02176 · Cited by 112
“, 2015; Petit and Vergès, 2017), and improved liver histology (Cuthbertson et al., 2012; Vilsbøll et al., 2012; Nishimura et al., 2017).”
BackgroundMechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders
Hazlehurst, J. M., & Tomlinson, J. W. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0296 · Cited by 97
Abushamat, L. A., Shah, P. A., Eckel, R. H., Harrison, S. A., & Barb, D. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.01.032 · Cited by 114
Dobson, R., Burgess, M. I., Sprung, V. S., Irwin, A., Hamer, M., Jones, J., Daousi, C., Adams, V. L., Kemp, G. J., Shojaee‐Moradie, F., et al. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.151 · Cited by 99
Self-citationSeghieri, M., Christensen, A. S., Andersen, A., Solini, A., Knop, F. K., & Vilsbøll, T. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00649 · Cited by 92
“In NAFLD patients, the increase in serum concentrations of total adiponectin following GLP-1RAs treatment may be consistent with a restoration of a dysfunctional adipose tissue (50).”
BackgroundCarbone, L. J., Angus, P. W., & Yeomans, N. D. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13026 · Cited by 91
Newer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 110
Self-citationCusi, K., Sattar, N., García‐Pérez, L. ‐., Pavo, I., Yu, M., Robertson, K. E., Karanikas, C. A., & Haupt, A. (2018) · Diabetic Medicine · doi:10.1111/dme.13697 · Cited by 89
Giorda, C. B., Nada, E., & Tartaglino, B. (2014) · Endocrine · doi:10.1007/s12020-014-0179-0 · Cited by 89
“Recently favorable data on liver fat accumulation in patients on either exenatide or liraglutide were published [75].”
BackgroundJensterle, M., Kocjan, T., Kravos, N. A., Pfeifer, M., & Janez, A. (2015) · Endocrine Research · doi:10.3109/07435800.2014.966385 · Cited by 86
“The exact interrelationship between the relevant amounts of visceral and subcutaneous adipose tissue loss in patients treated with GLP-1 RA is not fully clarified (35).”
BackgroundMultifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
Guerra, J. V. D. S., Dias, M. M. G., Brilhante, A. J. V. C., Terra, M. F., García‐Arévalo, M., & Figueira, A. C. M. (2021) · Nutrients · doi:10.3390/nu13082830 · Cited by 111
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
Lonardo, A., Ballestri, S., Targher, G., & Loria, P. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.965143 · Cited by 88
Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives
Jin, T., & Weng, J. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00069.2016 · Cited by 91
Pinyopornpanish, K., Leerapun, A., Pinyopornpanish, K., & Chattipakorn, N. (2021) · Gut and Liver · doi:10.5009/gnl20367 · Cited by 81
Tian, F., Zheng, Z., Zhang, D., He, S., & Shen, J. (2018) · Bioscience Reports · doi:10.1042/bsr20181304 · Cited by 80
Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action
Younossi, Z. M., & Henry, L. L. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0010 · Cited by 102
“Although SGLT2 inhibitors are also promising for improving hepatic steatosis, liver enzyme levels, BMI, and in fl ammatory markers, additional studies are needed to assess their safety and side effects (e.g., hypoglycemia, ketoacidosis, and urinary tract and genital infections) (108 – 111).”
BackgroundKahal, H., Abouda, G., Rigby, A. S., Coady, A. M., Kilpatrick, E. S., & Atkin, S. L. (2014) · Clinical Endocrinology · doi:10.1111/cen.12369 · Cited by 79
Modern approach to the clinical management of non-alcoholic fatty liver disease
Ben, M. D., Polimeni, L., Baratta, F., Pastori, D., Loffredo, L., & Angelico, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8341 · Cited by 89
Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin
Vanderheiden, A., Harrison, L. B., Warshauer, J. T., Adams-Huet, B., Li, X., Yuan, Q., Hulsey, K., Dimitrov, I., Yokoo, T., Jaster, A. W., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3906 · Cited by 76
“6) Diabetes duration, y 16 [12–23] 18 [13–27] Background medications, % Metformin 80.”
Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 85
Steven, S., Hollingsworth, K. G., Small, P. K., Woodcock, S. A., Pucci, A., Aribasala, B., Al‐Mrabeh, A., Batterham, R. L., & Taylor, R. (2016) · Diabetic Medicine · doi:10.1111/dme.13257 · Cited by 71
GLP-1 receptor agonists in NAFLD
Petit, J.-M., & Vergès, B. L. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30070-8 · Cited by 76
Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes
Kato, H., Nagai, Y., Ohta, A., Tenjin, A., Nakamura, Y., Tsukiyama, H., Sasaki, Y., Fukuda, H., Ohshige, T., Terashima, Y., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.008 · Cited by 70
Bi, Y., Zhang, B., Xu, W., Yang, H., Feng, W., Li, C., Tong, G., Li, M., Wang, X., Shen, S., et al. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0638-3 · Cited by 75
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
Hossain, N., Kanwar, P., & Mohanty, S. R. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/7109270 · Cited by 75
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Lv, X., Dong, Y., Hu, L., Lu, F., Zhou, C., & Qin, S. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.163 · Cited by 71
“A total of 6313 participants were studied, with a mean duration of 37 (12-144) weeks.”
BackgroundTang, W., Xu, Q., Hong, T., Tong, G., Feng, W., Shen, S., Bi, Y., & Zhu, D. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2713 · Cited by 65
“In one prospective clinical study, 25 of the 31 eligible T2DM patients completed GLP-1R agonist intervention [41].”
BackgroundGLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 64
“152 Likewise, on histology, 1 year of treatment with sitagliptin improved NASH severity.”
BackgroundZhu, Y., Xu, J., Zhang, D., Mu, X., Shi, Y. Y., Chen, S., Wu, Z., & Li, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.769069 · Cited by 65
“These agents act directly on human hepatocytes in vitro, reducing steatosis by decreasing de-novo lipogenesis and increasing fatty acid oxidation (34, 35).”
BackgroundKalra, S., Das, A. K., Sahay, R. K., Baruah, M. P., TIWASKAR, M. H., Das, S., Chatterjee, S., Saboo, B., Bantwal, G., Bhattacharya, S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0669-4 · Cited by 70
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
Portillo-Sánchez, P., & Cusi, K. J. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0027-7 · Cited by 59
“Liraglutide [69-75] GLP-1 receptor agonist ↓ ↓**^ Improved”
BackgroundThe Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Kosmalski, M., Ziółkowska, S., Czarny, P. L., Szemraj, J., & Pietras, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051375 · Cited by 62
Dhir, G., & Cusi, K. J. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000554 · Cited by 55
Rizvi, A. A., Patti, A. M., Giglio, R. V., Nikolić, D., Amato, A., Busaidi, N. A., Al‐Rasadi, K., Soresi, M., Banach, M., Montalto, G., et al. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1067299 · Cited by 54
“Several studies showed a reduction of the glycemic parameters in diabetic patient with NAFLD after liraglutide therapy [11,12], suggesting that its action on glycemic control and body weight (at a dose of 1.”
BackgroundInfluentialJordy, A. B., Kraakman, M. J., Gardner, T., Estevez, E., Kammoun, H. L., Weir, J. M., Kiens, B., Meikle, P. J., Febbraio, M. A., & Henstridge, D. C. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00547.2014 · Cited by 51
Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue
Dias, S., Paredes, S., & Ribeiro, L. V. P. T. (2018) · International Journal of Endocrinology · doi:10.1155/2018/2637418 · Cited by 57
“Authors anticipated that this effect is due to an increase in glucose tolerance, thus reducing hyperinsulinemia [193] followed by a decrease in lipogenesis rate and an increase in FA oxidation.”
BackgroundResultThe Gut Microbiome and Ferroptosis in MAFLD
Ji, J., Wu, L., Wei, J., Wu, J., & Guo, C. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00136 · Cited by 68
Non-alcoholic fatty liver disease: a diabetologist’s perspective
Pappachan, J. M., Antonio, F. A., Edavalath, M., & Mukherjee, A. (2013) · Endocrine · doi:10.1007/s12020-013-0087-8 · Cited by 52
“Preliminary data suggests improvement of hepatic lipid content in patients with T2DM treated with GLP-1 agonists [70].”
Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
Kalavalapalli, S., Bril, F., Guingab, J., Vergara, A., Garrett, T. J., Sunny, N. E., & Cusi, K. J. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0007 · Cited by 54
Krishnan, A., Schneider, C. V., Hadi, Y. B., Mukherjee, D., Alshehri, B. Y., & Alqahtani, S. A. (2023) · Diabetologia · doi:10.1007/s00125-023-06057-5 · Cited by 55
Liu, Y., Wei, R., & Hong, T. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.9090 · Cited by 55
GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction
Pastel, E., McCulloch, L. J., Ward, R., Joshi, S., Gooding, K. M., Shore, A. C., & Kos, K. (2017) · Clinical Science · doi:10.1042/cs20160803 · Cited by 49
GLP‐1 receptor agonists: effects on the progression of non‐alcoholic fatty liver disease
Liu, J., Wang, G., Jia, Y., & Xu, Y. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2580 · Cited by 48
“these agents have shown a novel therapeutic effect for NAFLD [12,13].”
BackgroundScheen, A. J. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0157-y · Cited by 49
“Finally, in another study, improved glucose control correlated with liver fat reduction in obese T2DM patients given the GLP-1 receptor agonists exenatide or liraglutide for 6 months [60].”
BackgroundMcCarty, M. F., & DiNicolantonio, J. J. (2015) · Open Heart · doi:10.1136/openhrt-2014-000205 · Cited by 51
Zhou, R., Lin, C., Cheng, Y., Zhuo, X., Li, Q., Xu, W., Zhao, L., & Yang, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.600175 · Cited by 48
“The use of GLP-1 agonist as a novel antidiabetic drug can alleviate lipid accumulation and inflammation in hepatocytes (Cuthbertson et al., 2012; Wang et al., 2014; Xu et al., 2014).”
BackgroundMedication use for the treatment of diabetes in obese individuals
Wilding, J. P. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4288-1 · Cited by 49
“SGLT2i and GLP-1 RAs may have other advantages when used in diabetes treatment; there is emerging evidence that they may reduce visceral, particularly hepatic, fat deposition [26].”
BackgroundJohansson, L., Hockings, P. D., JOHNSSON, E. K., Dronamraju, N., Maaske, J., García‐Sánchez, R., & Wilding, J. P. H. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14004 · Cited by 44
Ishii, S., Nagai, Y., Sada, Y., Fukuda, H., Nakamura, Y., Matsuba, R., Nakagawa, T., Kato, H., & Tanaka, Y. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3647 · Cited by 47
Pallayová, M., & Taheri, S. (2014) · Clinical Obesity · doi:10.1111/cob.12068 · Cited by 47
“In a study of 25 obese, type 2 diabetic adults with hepatic steatosis, a 6-month treatment with liraglutide/exenatide (glucagon-like peptide-1 receptor agonists) was associated with a 42% relative reduction in intrahepatic lipid content that correlated with the relative reduction in glycated haemoglobin (132).”
BackgroundThe preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy
He, Y., Ao, N., Yang, J., Wang, X., Jin, S., & Du, J. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2019.06.023 · Cited by 41
“Liraglutide, a GLP-1 analog, has been reported to decrease lipid deposition and inflammation in hepatocytes [29,30].”
BackgroundLi, D., Xu, X., Zhang, Y., Zhu, J., Ye, L., Lee, K., & Ma, J. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.05.051 · Cited by 42
Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease
Blaslov, K., Bulum, T., Zibar, K., & Duvnjak, L. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7356 · Cited by 39
Liu, C., Hu, M., Zhang, M., Li, F., Li, J., Zhang, J., Li, Y., Guo, H., Xu, P., Liu, L., et al. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.015 · Cited by 38
“Accumulating reports have verified the important role of GLP1 in lipid and glucose homeostasis as well as insulin sensitivity [8,14,34–37], inferring that ginsenosides may exert anti-hyperlipidemia effects by activating GLP-1 secretion, thereby mediating beneficial effects in lipid homeostasis and insulin resistance.”
BackgroundHöper, A. C., Salma, W., Sollie, S. J., Hafstad, A. D., Lund, J., Khalid, A. M., Raa, J., Aasum, E., & Larsen, T. S. (2013) · Journal of Nutrition · doi:10.3945/jn.113.182501 · Cited by 39
Li, S., Wang, X., Zhang, J., Li, J., Liu, X., Ma, Y., Han, C., Zhang, L., & Zheng, L. (2018) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20187299 · Cited by 36
“1590/1414-431X20187299 Brazilian Journal of Medical and Biological Research (2018) 51(8): e7299, http://dx.”
BackgroundTakeshita, Y., Takamura, T., Kita, Y., Otoda, T., Kato, K., Wakakuri, H., Yamada, M., Misu, H., Matsushima, Y., Kaneko, S., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12269 · Cited by 35
Metadata
- Authors
- Cuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., Pirmohamed, M., & Kemp, G. J.
- Affiliations
- University of Liverpool (GB)
- Aintree University Hospital (GB)
- Royal Liverpool University Hospital (GB)
- Countess of Chester Hospital (GB)
- Imperial College London (GB)
- Corresponding author
- Cuthbertson, Daniel J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-12-06
- Volume
- 7
- Issue
- 12
- Pages
- e50117
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3516516
- OpenAlex
- W2041468536
- Cited by
- 226
- References
- 37
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 9 · 2023: 12 · 2022: 15 · 2021: 15 · 2020: 22 · 2019: 12 · 2018: 19 · 2017: 14 · 2016: 22 · 2015: 18 · 2014: 35 · 2013: 13
- FWCI
- 16.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- WestminsterResearch (University of Westminster) (acceptedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- European Foundation for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, obesity, non-alcoholic fatty liver disease, intrahepatic lipid, hepatic steatosis, glycemic control, HbA1c, exenatide, liraglutide, visceral adipose tissue, subcutaneous adipose tissue, weight loss
- MeSH terms
- Liraglutide, Exenatide, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fatty Liver, Female, Humans, Hypoglycemic Agents, Liver, Male, Middle Aged, Obesity, Peptides, Prospective Studies, Venoms, Weight Loss, Body Mass Index, Adiposity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.